Xvivo Perfusion AB (publ) (STO: XVIVO)
Sweden
· Delayed Price · Currency is SEK
499.00
-3.00 (-0.60%)
Jan 9, 2025, 11:05 AM CET
Xvivo Perfusion AB Revenue
Xvivo Perfusion AB had revenue of 198.48M SEK in the quarter ending September 30, 2024, with 35.38% growth. This brings the company's revenue in the last twelve months to 750.59M, up 30.92% year-over-year. In the year 2023, Xvivo Perfusion AB had annual revenue of 597.54M with 43.88% growth.
Revenue (ttm)
750.59M
Revenue Growth
+30.92%
P/S Ratio
20.45
Revenue / Employee
4.66M
Employees
160
Market Cap
15.54B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 597.54M | 182.25M | 43.88% |
Dec 31, 2022 | 415.29M | 156.91M | 60.73% |
Dec 31, 2021 | 258.39M | 78.53M | 43.66% |
Dec 31, 2020 | 179.86M | -40.98M | -18.55% |
Dec 31, 2019 | 220.84M | 32.97M | 17.55% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Swedish Orphan Biovitrum AB | 25.44B |
Sectra AB | 3.14B |
Getinge AB | 33.59B |
Camurus AB | 1.69B |
Vitrolife AB | 3.56B |
Medicover AB | 22.60B |
Bonesupport Holding AB | 814.46M |
Elekta AB | 17.72B |